Skip to main content

$0.038 0.001 (2.70%)

High

$0.04

Low

$0.04

Trades

17

Turnover

$72,787

Volume

1,963,571
30 June 2023 at 3:59pm
Register to track CHM and receive email alerts.
Subject
CHM Ann: Initial Director's Interest Notice - JC

CHM Ann: Notice under section 708A

CHM Ann: Preliminary Final Report

CHM Ann: Chimeric Appoints Jennifer Chow as CEO & MD

CHM Ann: Notification regarding unquoted securities - CHM

CHM Ann: Application for quotation of securities - CHM

CHM Ann: Application for quotation of securities - CHM

CHM Ann: Release of ordinary shares from escrow

CHM Ann: IND clearance received from US FDA for CHM 1101

CHM Ann: Change of Director's Interest Notice - GM

CHM Ann: Dr Yi Lin appointed to Cellular Immunotherapy SAB

CHM Ann: Chimeric Therapeutics CDH17 Investor Webinar

CHM Ann: Chimeric licenses novel solid tumor CAR T therapy from Penn

CHM Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CHM Ann: Initial Director's Interest Notice - GM

CHM Ann: Celgene Veteran Dr George Matcham Appointed to Board

CHM Ann: Dr Li Ren Joins as Vice President Technical Operations

CHM Ann: Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial

CHM Ann: Appendix 2A and 708A Notice

CHM Ann: Proposed issue of Securities - CHM

CHM Ann: CLTX CAR T Abstract Accepted for Presentation at ASCO

CHM Ann: Appendix 4C - quarterly

CHM Ann: Successful Completion of First Patient Cohort Phase 1 Trial

CHM Ann: Investor Presentation

CHM Ann: Successful Completion of Dosing in First Patient Cohort

CHM Ann: Chimeric to Present at NWR Virtual Investor Conference

CHM Ann: Change of Director's Interest Notice - CE

CHM Ann: Half Yearly Report and Accounts

CHM Ann: Dr Bourk former KITE PHARMA Senior Executive Joins Chimeric

CHM Ann: Initial Director's Interest Notice (Amended) - PH

CHM Ann: Change of Director's Interest Notice - LC

CHM Ann: Initial Director's Interest Notice - CE

CHM Ann: Former Juno Executive Cindy Elkins Joins Chimeric Board

CHM Ann: Dr Yvonne Chen Appointed to CHM Scientific Advisory Board

CHM Ann: Change of Director's Interest Notice - LC

CHM Ann: Becoming a substantial holder - PH

CHM Ann: Initial Director's Interest Notice - PH

CHM Ann: Initial Director's Interest Notice - LC

CHM Ann: Initial Director's Interest Notice - LR

CHM Ann: Chimeric Therapeutics Commences Trading on the ASX

CHM Ann: Pre-Quotation Disclosure

CHM Ann: Top 20 Holders

CHM Ann: Distribution Schedule

CHM Ann: Securities Trading Policy

CHM Ann: Omnibus Incentive Plan Rules

CHM Ann: Annual Report 30 June 2020

CHM Ann: Constitution

CHM Ann: Prospectus

CHM Ann: Appendix 1A and Information Form and Checklist

CHM Ann: ASX Market Release - Admission and Quotation

Register to track CHM and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX